Generic Medicine Info
Indications and Dosage
Adult: Initially, 0.7 mg/kg; followed by a wkly dose of 1 mg/kg. Treatment period is usually 12 wk, to continue only when there is improvement. Max: 200 mg/dose.
Known hypersensitivity. Should not be used in patients with clinically important infections.
Special Precautions
Monitor platelet counts before and during treatment. Acellular, live and live-attenuated vaccines should not be given during treatment. Pregnancy and lactation.
Adverse Reactions
Headache, fever, nausea, vomiting.
Drug Interactions
Avoid concurrent admin of other immunosuppressive agents or with phototherapy.
Description: Efalizumab is a recombinant humanized anti-CD11a monoclonal antibody functioning as an immunosuppressive agent used in the management of moderate to severe chronic plaque psoriasis.
Absorption: Plasma concentrations peak 1-2 days after SC inj; bioavailability: About 50%.
Metabolism: Metabolised by intracellular degradation.
Excretion: Time to elimination after the last dose is about 25 days.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Efalizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in